DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

被引：2
|
作者：
Elgart, J. F. [1 ]
Prestes, M. [1 ]
Gonzalez, L. [1 ]
Aschner, P. [2 ]
Garrido Lecca, S. [3 ]
Aiello, E. [4 ]
Jimenez, C. [5 ]
Gagliardino, J. J. [1 ]
机构：
[1] UNLP CONICET La Plata, Ctr Colaborador OPS OMS, CENEXA Ctr Endocrinol Expt & Aplicada, Buenos Aires, DF, Argentina
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Bristol Myers Squibb Co, Lima, Peru
[4] Bristol Myers Squibb Co, Buenos Aires, DF, Argentina
[5] Bristol Myers Squibb Co, Bogota, Colombia
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1442
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A247 / A247
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes
    Brown, RR
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 : S24 - S27
  • [22] Cost-effectiveness analysis of levetiracetam add-on therapy for the treatment of partial onset seizures: A comparative analysis versus topiramate
    Godfroid, P
    Pimentel, J
    [J]. EPILEPSIA, 2005, 46 : 271 - 272
  • [23] Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes
    Zupa, Margaret F.
    Codario, Ronald A.
    Smith, Kenneth J.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (15) : 1133 - 1141
  • [24] COST-EFFECTIVENESS OF TYPE 2 DIABETES (T 2DM) TREATMENT WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN IN THE DOMINICAN REPUBLIC AND GUATEMALA
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A671 - A672
  • [25] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [26] Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
    M. Charokopou
    P. McEwan
    S. Lister
    L. Callan
    K. Bergenheim
    K. Tolley
    R. Postema
    R. Townsend
    M. Roudaut
    [J]. BMC Health Services Research, 15
  • [27] Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    [J]. BMC HEALTH SERVICES RESEARCH, 2015, 15
  • [28] Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
    Rosenstock, Julio
    Mathieu, Chantal
    Chen, Hungta
    Garcia-Sanchez, Ricardo
    Saraiva, Gabriela Luporini
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2018, 62 (04): : 424 - 430
  • [29] Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
    Sabale, Ugne
    Ekman, Mattias
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    [J]. PRIMARY CARE DIABETES, 2015, 9 (01) : 39 - 47
  • [30] COST-EFFECTIVENESS OF CANNABIDIOL ADD-ON THERAPY VERSUS PLACEBO FOR THE TREATMENT OF SEIZURES IN TUBEROUS SCLEROSIS COMPLEX
    Bowditch, S.
    Burke, C.
    Crossan, C.
    Hemstock, M.
    Tyas, E.
    Lee, D.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S56 - S56
12345